Gene expression alterations in human colon cancer xenograft treated with anti-VEGF antibody
Ontology highlight
ABSTRACT: Recent randomized clinical trial revealed the additional effect of bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF)-A, to conventional chemotherapy on survival of patients with metastatic colorectal cancer. However, a number of preclinical reports indicate resistant mechanisms to anti-angiogenic therapy in several tumor models. We investigated the phenotypic alterations of colorectal cancer xenograft during antiangiogenic therapy.
ORGANISM(S): Homo sapiens
PROVIDER: GSE47087 | GEO | 2013/05/25
SECONDARY ACCESSION(S): PRJNA203538
REPOSITORIES: GEO
ACCESS DATA